The Enterprise Value as of September 2024 (TTM) for Gain Therapeutics, Inc. (GANX) is 21.66M

According to Gain Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 21.66M. This represents a change of -40.30% compared to the average of 36.29M of the last 4 quarters.

Gain Therapeutics, Inc. (GANX) Historical Enterprise Value (quarterly & annually)

How has GANX Enterprise Value performed in the past?

The mean historical Enterprise Value of Gain Therapeutics, Inc. over the last ten years is 68.17M. The current 21.66M Enterprise Value has changed 3.08% with respect to the historical average. Over the past ten years (40 quarters), GANX's Enterprise Value was at its highest in in the December 2020 quarter at 120.68M. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.

Gain Therapeutics, Inc. (GANX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Gain Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gain Therapeutics, Inc. (GANX) Average Enterprise Value

How has GANX Enterprise Value performed in the past?

The current Enterprise Value of Gain Therapeutics, Inc. (GANX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Gain Therapeutics, Inc. (GANX) Enterprise Value vs. Peers

How is GANX’s Enterprise Value compared to its peers?

Gain Therapeutics, Inc.’s Enterprise Value is greater than BioVie Inc. (-2789058.00), greater than IN8bio, Inc. (9.97M), less than NewAmsterdam Pharma Company N.V. (995.70M), greater than Cue Biopharma, Inc. (8.64M), greater than TFF Pharmaceuticals, Inc. (3.28M), less than aTyr Pharma, Inc. (138.44M), less than Lantern Pharma Inc. (27.72M), less than Eliem Therapeutics, Inc. (0), less than Inhibrx, Inc. (329.54M), less than Merrimack Pharmaceuticals, Inc. (27.63M), greater than Celcuity Inc. (-10189682.00), less than Enliven Therapeutics, Inc. (626.69M), less than Molecular Partners AG (960.41M), greater than MediciNova, Inc. (-9950721.74), less than Anebulo Pharmaceuticals, Inc. (44.44M), less than Champions Oncology, Inc. (49.05M), less than Cyteir Therapeutics, Inc. (70.81M), greater than null (-20511738.00),

Build a custom stock screener for Gain Therapeutics, Inc. (GANX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gain Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gain Therapeutics, Inc. (GANX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gain Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.